Press release
Aariya Regulatory Launches eCTD Publishing Services
Aariya Regulatory, one of the most trusted names to offer specialized regulatory services for global generic and bio-pharma companies, today announced the launch of eCTD publishing services using licensed software to prepare, submit and maintain electronic dossiers for ANDA, IND, NDA, MAA and lifecycle submissions.On this occasion, Sachin Verma, Founder and Director of Aariya Regulatory Services was quoted saying "If you decide to go eCTD but don't want to commit to an in-house soft- and/or hardware solution yet, with eCTD Solutions we at Aariya can now offer a complete package of eCTD submission service at your disposal." "We are confident that the tools included in the eCTD software package is going to significantly reduce our effort hours and will now help us offer an unmatched level of personalized service to our clients" added Pallab Roy, Co-founder and Chief Regulatory Consultant of Aariya.
Aariya can now assist their existing as well as future clients with all aspects of eCTD submissions for all major markets, including (but not limited to) the US (FDA), EU region, Switzerland (Swissmedic), Canada (Health Canada), Australia (TGA) / New Zealand (Medsafe), South Africa (MCC), GCC (SFDA), Jordan (JFDA) and Thailand (FDA).
Media Contact:
Aariya Regulatory Services Pvt. Ltd.
108, First Floor, F-6&7, Vishwakarma Colony, Pulpehladpur, New Delhi- 110044, India
Phone: +1-609-945-3618
Email: contact@aariya.net
About AARIYA Regulatory
Founded on the principle of clients being the real assets as well as the biggest advocates of a consulting service company, AARIYA Regulatory provides sustainable outsourcing of all regulatory affairs services across all major markets around the globe, which any generic pharmaceutical organization requires to sharpen their competitive edge in this era of cut-throat competition. Be it simple market intelligence, new submission guidance, life-cycle management, electronic publishing assistance or more complex expertise such as building the regulatory strategy, AARIYA continues to evolve its offerings and lead in the definition and execution of new business models for the generic pharmaceutical industry. For more information, visit www.aariya.net.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aariya Regulatory Launches eCTD Publishing Services here
News-ID: 2063506 • Views: …
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
